Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nuchido Limited has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units. ROBINSON, MIKHAIL O'DONNEL is the busiest examiner, with 1 pending matter. The profile therefore shows prosecution activity distributed across more than one examination assignment, while the busiest examiner is responsible for 1 of the pending matters.
This structure calls for matter-by-matter docket review rather than a single uniform response approach. Counsel should identify which action belongs to which examiner and art unit, then tailor amendments and arguments to each record. A coordinated portfolio position remains useful for claim scope and disclosure support, but the separate examination paths should be monitored independently so that a response to one action does not overlook the other.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.3% | +43.1% |
| OLSON, ANDREA STEFFEL | 1 | 62.4% | -11.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025307 | SENOLYTIC COMPOUNDS AND COMPOSITIONS | ROBINSON, MIKHAIL O'DONNEL | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025307 | SENOLYTIC COMPOUNDS AND COMPOSITIONS | ROBINSON, MIKHAIL O'DONNEL | 14d |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18025307 | SENOLYTIC COMPOUNDS AND COMPOSITIONS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103§112 | Final Rejection | 14d | Pending | Mar 08, 2023 |
| 16980207 | METHOD OF TREATMENT | OLSON, ANDREA STEFFEL | 1693 | §103 | Final Rejection | 73d overdue | Pending | Sep 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNuchido Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Mikhail O'Donnel Robinson has the most, with 1 of Nuchido Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
